<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cardiovasc Disord</journal-id><journal-title>BMC Cardiovascular Disorders</journal-title><issn pub-type="epub">1471-2261</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16762079</article-id><article-id pub-id-type="pmc">1524985</article-id><article-id pub-id-type="publisher-id">1471-2261-6-26</article-id><article-id pub-id-type="doi">10.1186/1471-2261-6-26</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Modular prevention of heart disease following acute coronary syndrome (ACS) [ISRCTN42984084]</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Redfern</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>julieredfern@dodo.com.au</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Ellis</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>elizabethellis@ozemail.com.au</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Briffa</surname><given-names>Tom</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>T.Briffa@curtin.edu.au</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Freedman</surname><given-names>SB</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>ben@gmp.usyd.edu.au</email></contrib></contrib-group><aff id="I1"><label>1</label>School of Physiotherapy, University of Sydney, Sydney, Australia</aff><aff id="I2"><label>2</label>School of Physiotherapy, Curtin University of Technology, Perth, Australia</aff><aff id="I3"><label>3</label>Department of Cardiology, Concord Repatriation General Hospital, Sydney, Australia</aff><aff id="I4"><label>4</label>Faculty of Medicine, University of Sydney, Sydney, Australia</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>9</day><month>6</month><year>2006</year></pub-date><volume>6</volume><fpage>26</fpage><lpage>26</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2261/6/26"></ext-link><history><date date-type="received"><day>5</day><month>4</month><year>2006</year></date><date date-type="accepted"><day>9</day><month>6</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 Redfern et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Redfern et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3377" xml_f="3387" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3398" xml_f="4036" txt_i="22" txt_f="660">Coronary heart disease (CHD) is a major cause of morbidity and mortality in Australia and it is recommended that all persons with unstable angina (UA) or myocardial infarction (MI) participate in secondary prevention as offered in cardiac rehabilitation (CR) programs. However, the majority of patients do not access standard CR and have higher baseline coronary risk and poorer knowledge of CHD than those persons due to commence CR. The objective of this study is to investigate whether a modular guided self-choice approach to secondary prevention improves coronary risk profile and knowledge in patients who do not access standard CR.</offsets></p></sec><sec><title><offsets xml_i="4058" xml_f="4072" txt_i="662" txt_f="676">Methods/Design</offsets></title><p><offsets xml_i="4083" xml_f="4767" txt_i="677" txt_f="1361">This randomised controlled trial with one year follow-up will be conducted at a tertiary referral hospital. Participants eligible for but not accessing standard CR will be randomly allocated to either a modular or conventional care group. Modular care will involve participation in individualised modules that involve choice, goal-setting and coaching. Conventional care will involve ongoing heart disease management as directed by the participant's doctors. Both modular and conventional groups will be compared with a contemporary reference group of patients attending CR. Outcomes include measured modifiable risk factors, relative heart disease risk and knowledge of risk factors.</offsets></p></sec><sec><title><offsets xml_i="4789" xml_f="4799" txt_i="1363" txt_f="1373">Discussion</offsets></title><p><offsets xml_i="4810" xml_f="4994" txt_i="1374" txt_f="1558">We present the rationale and design of a randomised controlled trial testing a modular approachfor the secondary prevention of coronary heart disease following acute coronary syndrome.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="5056" xml_f="5066" txt_i="1567" txt_f="1577">Background</offsets></title><p><offsets xml_i="5077" xml_f="5204" txt_i="1578" txt_f="1705">Coronary heart disease (CHD) is a major cause of morbidity and mortality in Australia and is associated with significant cost [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5235" xml_f="5236" txt_i="1705" txt_f="1706">1</offsets></xref><offsets xml_i="5243" xml_f="5383" txt_i="1706" txt_f="1846">]. Australian guidelines recommend all persons with unstable angina (UA) or myocardial infarction (MI) participate in secondary prevention [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5414" xml_f="5415" txt_i="1846" txt_f="1847">2</offsets></xref><offsets xml_i="5422" xml_f="5733" txt_i="1847" txt_f="2158">] incorporating risk factor management. Risk factor modification including lifestyle change and the use of vasoprotective medications is an effective means extending overall survival, reducing non-fatal cardiovascular events, decreasing the need for coronary revascularisation, enhancing quality of life (QOL) [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5764" xml_f="5765" txt_i="2158" txt_f="2159">3</offsets></xref><offsets xml_i="5772" xml_f="5819" txt_i="2159" txt_f="2206">] and improving coronary endothelial function [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="5850" xml_f="5851" txt_i="2206" txt_f="2207">4</offsets></xref><offsets xml_i="5858" xml_f="5859" txt_i="2207" txt_f="2208">,</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="5890" xml_f="5891" txt_i="2208" txt_f="2209">5</offsets></xref><offsets xml_i="5898" xml_f="6166" txt_i="2209" txt_f="2477">]. Importantly, CHD is a chronic illness that is best managed when positive health behaviors become integrated into long-term lifestyle habits therefore, strategies are needed to motivate and support patients to consistently follow multidimensional treatment regimens.</offsets></p><p><offsets xml_i="6173" xml_f="6249" txt_i="2478" txt_f="2554">Cardiac rehabilitation is a widely recognised form of secondary prevention [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="6280" xml_f="6281" txt_i="2554" txt_f="2555">6</offsets></xref><offsets xml_i="6288" xml_f="6333" txt_i="2555" txt_f="2600">], but participation rates are low (10–30%) [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="6364" xml_f="6365" txt_i="2600" txt_f="2601">7</offsets></xref><offsets xml_i="6372" xml_f="6373" txt_i="2601" txt_f="2602">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="6404" xml_f="6405" txt_i="2602" txt_f="2603">8</offsets></xref><offsets xml_i="6412" xml_f="6507" txt_i="2603" txt_f="2698">] because of transport difficulties, work and social commitments and a lack of perceived need [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6538" xml_f="6539" txt_i="2698" txt_f="2699">9</offsets></xref><offsets xml_i="6546" xml_f="6708" txt_i="2699" txt_f="2861">]. Despite clear short-term benefits for attendees, large groups of patients are not benefiting, which presents an opportunity and challenge to improve CHD care [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6740" xml_f="6742" txt_i="2861" txt_f="2863">10</offsets></xref><offsets xml_i="6749" xml_f="7017" txt_i="2863" txt_f="3131">]. Importantly, there are limited studies reporting the risk profile of patients not accessing formal rehabilitation. One observational Australian study demonstrated that non-participants were at higher risk of recurrent events than patients attending rehabilitation [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="7049" xml_f="7051" txt_i="3131" txt_f="3133">11</offsets></xref><offsets xml_i="7058" xml_f="7230" txt_i="3133" txt_f="3305">]. Similarly, functional impairment has been shown to be the strongest predictor of non-participation in cardiac rehabilitation after coronary artery bypass graft surgery [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="7262" xml_f="7264" txt_i="3305" txt_f="3307">10</offsets></xref><offsets xml_i="7271" xml_f="7430" txt_i="3307" txt_f="3466">]. These findings are of major concern because the patients who stand to benefit the most from secondary prevention are the people least likely to participate.</offsets></p><p><offsets xml_i="7437" xml_f="7603" txt_i="3467" txt_f="3633">One pilot study has clinically investigated secondary prevention of CHD using a 'modular' approach and demonstrated enhanced completion rates and cost effectiveness [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="7635" xml_f="7637" txt_i="3633" txt_f="3635">12</offsets></xref><offsets xml_i="7644" xml_f="8219" txt_i="3635" txt_f="4210">]. For the study, a metropolitan cardiac rehabilitation program was offered as individual components, or modules, based on patient need rather than an all-or-nothing exercise-based approach. The pilot study was an important step from standard cardiac rehabilitation however, the modules were still conducted in a group environment and were predominantly based on education without formal goal setting and follow-up. Results of the pilot study suggest it is likely that the development and evaluation of more detailed unique risk factor modules may enhance long-term outcomes.</offsets></p><p><offsets xml_i="8226" xml_f="8439" txt_i="4211" txt_f="4424">The inclusion of multidimensional behavior modification techniques such as goal setting and offering a wide range of individually tailored services may enhance compliance with long-term risk factor interventions [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="8471" xml_f="8473" txt_i="4424" txt_f="4426">13</offsets></xref><offsets xml_i="8480" xml_f="8661" txt_i="4426" txt_f="4607">]. For chronic disease, it is important to conceptualise change in a positive light to reduce anxiety about the disease rather than focusing on negative aspects of making a change [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="8693" xml_f="8695" txt_i="4607" txt_f="4609">14</offsets></xref><offsets xml_i="8702" xml_f="8896" txt_i="4609" txt_f="4803">]. Setting of mutually-agreed, realistic and readily identifiable goals with clear time frames helps enhance active patient orientation and motivation and therefore facilitates behavior change [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="8928" xml_f="8930" txt_i="4803" txt_f="4805">14</offsets></xref><offsets xml_i="8937" xml_f="8938" txt_i="4805" txt_f="4806">,</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="8970" xml_f="8972" txt_i="4806" txt_f="4808">15</offsets></xref><offsets xml_i="8979" xml_f="9147" txt_i="4808" txt_f="4976">]. Further, the inclusion of a rating of confidence for goal achievement may improve the health professional's insight into a patient's intrinsic motivation to change [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="9179" xml_f="9181" txt_i="4976" txt_f="4978">14</offsets></xref><offsets xml_i="9188" xml_f="9190" txt_i="4978" txt_f="4980">].</offsets></p><p><offsets xml_i="9197" xml_f="9436" txt_i="4981" txt_f="5220">Facilitation of collaborative relationships, shared decision-making, offering choice and communication of expectations in a supportive environment helps motivate behavior change and therefore contributes to the disease management process [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="9468" xml_f="9470" txt_i="5220" txt_f="5222">15</offsets></xref><offsets xml_i="9477" xml_f="9478" txt_i="5222" txt_f="5223">,</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="9510" xml_f="9512" txt_i="5223" txt_f="5225">16</offsets></xref><offsets xml_i="9519" xml_f="9697" txt_i="5225" txt_f="5403">]. Formation of collaborative relationships decreases patient anxiety and dissatisfaction that is often related to uncertainty and lack of information, explanation and feedback [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="9729" xml_f="9731" txt_i="5403" txt_f="5405">17</offsets></xref><offsets xml_i="9738" xml_f="9860" txt_i="5405" txt_f="5527">]. Studies have demonstrated that encouraging patients to participate in treatment decisions improves health status, QOL [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="9892" xml_f="9894" txt_i="5527" txt_f="5529">18</offsets></xref><offsets xml_i="9901" xml_f="9902" txt_i="5529" txt_f="5530">,</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="9934" xml_f="9936" txt_i="5530" txt_f="5532">19</offsets></xref><offsets xml_i="9943" xml_f="9995" txt_i="5532" txt_f="5584">], satisfaction, compliance and treatment outcomes [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="10027" xml_f="10029" txt_i="5584" txt_f="5586">20</offsets></xref><offsets xml_i="10036" xml_f="10175" txt_i="5586" txt_f="5725">]. More specifically, patients with a higher degree of active orientation are more likely to comply with treatment recommendations for BP [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="10207" xml_f="10209" txt_i="5725" txt_f="5727">16</offsets></xref><offsets xml_i="10216" xml_f="10251" txt_i="5727" txt_f="5762">], diabetes and physical activity [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="10283" xml_f="10285" txt_i="5762" txt_f="5764">21</offsets></xref><offsets xml_i="10292" xml_f="10479" txt_i="5764" txt_f="5951">]. Offering choice, in situations where there are several management options based on individual preferences or circumstances is a further method of enhancing active patient orientation [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="10511" xml_f="10513" txt_i="5951" txt_f="5953">22</offsets></xref><offsets xml_i="10520" xml_f="10697" txt_i="5953" txt_f="6130">]. It is also suggested that options offered as a menu of strategies are more successful because it encourages each patient's task to be one of "choosing rather than refuting" [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="10729" xml_f="10731" txt_i="6130" txt_f="6132">14</offsets></xref><offsets xml_i="10738" xml_f="10896" txt_i="6132" txt_f="6290">]. We have chosen the term 'guided self-choice' to describe this model which creates a collaborative encounter, similar to the spirit of behavior counseling [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="10928" xml_f="10930" txt_i="6290" txt_f="6292">23</offsets></xref><offsets xml_i="10937" xml_f="10939" txt_i="6292" txt_f="6294">].</offsets></p><p><offsets xml_i="10946" xml_f="11199" txt_i="6295" txt_f="6548">The objective of this study is to investigate whether a modular guided self-choice approach to secondary prevention improves coronary risk profile and knowledge in acute coronary syndrome (ACS) patients who do not access standard cardiac rehabilitation.</offsets></p></sec><sec><title><offsets xml_i="11221" xml_f="11235" txt_i="6550" txt_f="6564">Methods/Design</offsets></title><sec><title><offsets xml_i="11255" xml_f="11261" txt_i="6565" txt_f="6571">Design</offsets></title><p><offsets xml_i="11272" xml_f="11964" txt_i="6572" txt_f="7264">This randomised controlled trial with one year follow-up will be conducted at a tertiary referral hospital in Sydney, Australia. Participants not attending standard cardiac rehabilitation will be randomly allocated to either a modular secondary prevention (experimental) or a conventional care (control) group. A third contemporary group of patients attending standard cardiac rehabilitation will also be recruited (reference group). Ethical approval for the study has been granted by both the Central Sydney Area Health Service CRGH Zone and the University of Sydney Human Research Ethics Committees. Written and informed consent will be obtained from all participants prior to commencement.</offsets></p><p><offsets xml_i="11971" xml_f="12417" txt_i="7265" txt_f="7711">Independent variables are the identification of individualised risk factor goals and participation in self chosen secondary prevention modules. The dependent variables are assessment of cardiac risk factors, the achievement of risk factor goals, unplanned hospital readmissions, quality of life, relative cardiac risk and knowledge of risk factors. The measurement and recording of experimental variables will be conducted under blind conditions.</offsets></p></sec><sec><title><offsets xml_i="12439" xml_f="12455" txt_i="7713" txt_f="7729">Study population</offsets></title><p><offsets xml_i="12466" xml_f="12684" txt_i="7730" txt_f="7948">To establish a recruitment database, a list of all admissions to a single metropolitan tertiary referral hospital in Sydney Australia, with an ACS during a 10 month period, was obtained using diagnostic related codes [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="12716" xml_f="12718" txt_i="7948" txt_f="7950">24</offsets></xref><offsets xml_i="12725" xml_f="13202" txt_i="7950" txt_f="8427">] for UA (F72A, F72B), MI (F41A, F41B, F60A, F60B) and chest pain (F74Z). For all admitted patients, the hospital medical records were reviewed to determine secondary prevention eligibility. Reasons for ineligibility included geography (living outside a 20 km radius of the hospital), insufficient English language to provide informed consent, congestive heart failure, the presence of a severe co-morbidity (eg, end stage renal disease, Parkinson's disease, cancer) and death.</offsets></p><p><offsets xml_i="13209" xml_f="13289" txt_i="8428" txt_f="8508">Inclusion criteria for the randomised conventional care and modular groups were:</offsets></p><p><offsets xml_i="13296" xml_f="13507" txt_i="8509" txt_f="8720">- No previous attendance at a formal cardiac rehabilitation program including those who refused the initial invitation to participate and those who failed to attend the initial cardiac rehabilitation assessment.</offsets></p><p><offsets xml_i="13514" xml_f="13572" txt_i="8721" txt_f="8779">- Diagnosis of ACS in the six months prior to recruitment.</offsets></p><p><offsets xml_i="13579" xml_f="13659" txt_i="8780" txt_f="8860">- Ability to understand sufficient English to give written and informed consent.</offsets></p><p><offsets xml_i="13666" xml_f="13739" txt_i="8861" txt_f="8934">Inclusion criteria for non-randomised standard rehabilitation group were:</offsets></p><p><offsets xml_i="13746" xml_f="13860" txt_i="8935" txt_f="9049">- Commencing attendance at the CRGH cardiac rehabilitation program during the data collection period of the study.</offsets></p><p><offsets xml_i="13867" xml_f="13925" txt_i="9050" txt_f="9108">- Diagnosis of ACS in the six months prior to recruitment.</offsets></p><p><offsets xml_i="13932" xml_f="14012" txt_i="9109" txt_f="9189">- Ability to understand sufficient English to give written and informed consent.</offsets></p><p><offsets xml_i="14019" xml_f="14095" txt_i="9190" txt_f="9266">Exclusion criteria were the same for all three groups in the study and were:</offsets></p><p><offsets xml_i="14102" xml_f="14175" txt_i="9267" txt_f="9340">- Clinical diagnosis of uncompensated, severe cardiac failure (Class IV).</offsets></p><p><offsets xml_i="14182" xml_f="14217" txt_i="9341" txt_f="9376">- Uncontrolled arrhythmia or angina</offsets></p><p><offsets xml_i="14224" xml_f="14263" txt_i="9377" txt_f="9416">- Severe or symptomatic aortic stenosis</offsets></p><p><offsets xml_i="14270" xml_f="14313" txt_i="9417" txt_f="9457">- Persistent hypotension (SBP &lt; 90 mmHg)</offsets></p><p><offsets xml_i="14320" xml_f="14513" txt_i="9458" txt_f="9651">- Clinical diagnosis of a severe co-existing medical condition that would prevent participation (eg, dementia, a rapidly deteriorating terminal illness or severe or active rheumatoid arthritis)</offsets></p><p><offsets xml_i="14520" xml_f="14943" txt_i="9652" txt_f="10075">Once the database of eligible patients is constructed, all patients will be contacted by mail and telephone and asked to volunteer for research investigating heart disease risk factors. Recruitment mail-outs will be conducted in batches of 30 to enable staggered recruitment over approximately six months. Patients will be contacted within two weeks of the mail-out to establish whether they would be prepared to volunteer.</offsets></p></sec><sec><title><offsets xml_i="14965" xml_f="14981" txt_i="10077" txt_f="10093">Group allocation</offsets></title><p><offsets xml_i="14992" xml_f="15584" txt_i="10094" txt_f="10686">For the standard cardiac rehabilitation group, participants will be consecutively recruited prior to commencement of outpatient cardiac rehabilitation. Patients who are eligible for but not participating in cardiac rehabilitation will be randomly allocated to either their modular or conventional care group immediately following completion of the baseline assessment. Therefore, the researcher conducting each baseline assessment will be blinded to group allocation. Prior to study commencement, a computer-generated allocation sequence will be constructed using randomly permutated blocks [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="15616" xml_f="15618" txt_i="10686" txt_f="10688">25</offsets></xref><offsets xml_i="15625" xml_f="16149" txt_i="10688" txt_f="11212">]. An individual not involved in the study recruitment, data collection or analysis will produce consecutively numbered sealed opaque envelopes containing each participant's allocation. Following baseline assessment, the researcher will select the next consecutively numbered envelope and open it to reveal the allocated group. They will then notate the unique patient identifier on the front on the participants cover sheet. Therefore, group allocation will be concealed from the researcher conducting baseline assessments.</offsets></p></sec><sec><title><offsets xml_i="16171" xml_f="16187" txt_i="11214" txt_f="11230">Outcome measures</offsets></title><p><offsets xml_i="16198" xml_f="16778" txt_i="11231" txt_f="11811">Assessments will be conducted in the hospital consulting rooms or in the participant's home, if they are unable to travel to the hospital. Demographic, subjective and objective information will be obtained during face-to-face assessments at baseline, three and 12 months. Information will include past history, nature of ACS, family history, age, medications and dose, presence of other cardiovascular disease and the nature and date of any revascularisation. In addition, contact details for each participant, their general practitioner and their cardiologist will be documented.</offsets></p><p><offsets xml_i="16785" xml_f="17427" txt_i="11812" txt_f="12454">At three and 12 month follow-up, all baseline measures will be repeated during face-to-face assessments by a researcher blinded to group allocation. Additional collected information will include – details of unplanned hospital admissions, medications and doses along with details of any health interventions undertaken by the participant pertaining to their heart health, such as visits to the GP and attendance at community programs. For participants in the standard rehabilitation group, details of participation in the cardiac rehabilitation program will also be recorded such as duration and attendance at exercise and education sessions.</offsets></p><p><offsets xml_i="17434" xml_f="18079" txt_i="12455" txt_f="13100">Modifiable risk factors to be measured are serum cholesterol, BP, smoking status, physical activity, overweight and depression. Lipids and substrates will be measured on a fasting blood sample within two weeks of assessment date. Participants will be referred to local pathology clinics by their primary care doctor and will visit the clinics by their own arrangement. Blood samples will be analysed for determination of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG). Repeat blood tests will be carried out at the same pathology clinic wherever possible.</offsets></p><p><offsets xml_i="18086" xml_f="18417" txt_i="13101" txt_f="13432">Resting BP will be measured from the brachial artery using an Omron digital automatic BP (Omron Healthcare Co Ltd Model M5, Japan). The automatic BP monitor will be calibrated against a mercury sphygmomanometer prior to study commencement and has been demonstrated to be accurate. The Omron M6 is accurate for BP to within 3 mmHg [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="18449" xml_f="18451" txt_i="13432" txt_f="13434">26</offsets></xref><offsets xml_i="18458" xml_f="18618" txt_i="13434" txt_f="13594">] and fulfills the recommendation criteria of the international protocol when tested against a mercury sphygmomanometer for diastolic and systolic BP readings [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="18650" xml_f="18652" txt_i="13594" txt_f="13596">27</offsets></xref><offsets xml_i="18659" xml_f="18913" txt_i="13596" txt_f="13850">]. For measurement, appropriate cuff size will be selected, each participant will be seated with the right arm supported and two consecutive blood pressure readings will be collected with one minute interval according to previously published guidelines [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="18945" xml_f="18947" txt_i="13850" txt_f="13852">28</offsets></xref><offsets xml_i="18954" xml_f="18956" txt_i="13852" txt_f="13854">].</offsets></p><p><offsets xml_i="18963" xml_f="19513" txt_i="13855" txt_f="14405">Smoking status will be initially assessed by analysis of carbon monoxide (CO) levels using a hand-held breath analyzer or CO meter (Bedfont micro smokerlyzer, Scientific Ltd, England) using new mouthpieces (Airmet Scientific EC50MP500, Victoria Australia) for each participant, for infection control purposes. Participants will be expected to blow into the mouthpiece for the 15 seconds and the result are to be recorded in parts per million (ppm). The criteria for recent, within the past 24 hours, smoking will be an expired CO greater than 5 ppm [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="19545" xml_f="19547" txt_i="14405" txt_f="14407">29</offsets></xref><offsets xml_i="19554" xml_f="19849" txt_i="14407" txt_f="14702">]. Smoking status will be confirmed with self report to identify participants who concealed their true smoking status. Participants will be asked whether they had ever smoked, how long since they started or stopped and if they smoked, what is/was the average number of cigarettes smoked per day.</offsets></p><p><offsets xml_i="19856" xml_f="19968" txt_i="14703" txt_f="14815">Physical activity levels will be assessed using the International Physical Activity Questionnaire (IPAQ) score [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="20000" xml_f="20002" txt_i="14815" txt_f="14817">30</offsets></xref><offsets xml_i="20009" xml_f="20430" txt_i="14817" txt_f="15238">]. The short, last-seven-days, self-administered format (last revised August 2002) comprises seven questions that seek information about the duration and frequency of vigorous and moderate physical activity as well as rest and walking in the past seven days. The IPAQ was developed as an international measure of physical activity, for use in adults, and has been tested for reliability and validity across 12 countries [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="20462" xml_f="20464" txt_i="15238" txt_f="15240">31</offsets></xref><offsets xml_i="20471" xml_f="20763" txt_i="15240" txt_f="15532">]. For final scoring, responses are divided into three categories, MET-minutes per week, average time spent sitting per day and a categorical level of physical activity. The categorical score is further divided into three levels – insufficiently active, sufficient activity and highly active.</offsets></p><p><offsets xml_i="20770" xml_f="20860" txt_i="15533" txt_f="15623">For assessment of depressive mood, the Cardiac Depression Scale (CDS) score will be used [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="20892" xml_f="20894" txt_i="15623" txt_f="15625">32</offsets></xref><offsets xml_i="20901" xml_f="21603" txt_i="15625" txt_f="16323">]. The CDS was developed from the responses of cardiac outpatients and comprises 26 items with subscales relating to sleep, uncertainty, mood, cognition, hopelessness and inactivity. Some items are scored in reverse and raw scores are used for analysis where higher scores indicate depressed mood and a score of greater than 90 represents depressive mood. When assessed for test-retest reliability over two weeks scores were 64.9 ± 23.3 (mean ± SD) and 63.1 ± 23.0 with correlation coefficient of 0.86 and score difference of -1.9 ± 12.2 (mean ± SD). Permission has been obtained to administer the CDS from Professor Hare, Department of Cardiology (Austin &amp; Repatriation Medical Centre, Australia).</offsets></p><p><offsets xml_i="21610" xml_f="21734" txt_i="16324" txt_f="16448">For assessment of overweight, body mass index (BMI) will be calculated using the standard equation (BMI = weight kg/height m</offsets><sup><offsets xml_i="21739" xml_f="21740" txt_i="16448" txt_f="16449">2</offsets></sup><offsets xml_i="21746" xml_f="22109" txt_i="16449" txt_f="16812">). Each participant's body weight will be measured when lightly clothed and in bare feet using digital scales (Tanita EB727, Australia) to the nearest 0.1 kg. Height will be measured without shoes using a standiometer (Stature Meter 2 m 1013522, Livingston International Pty Ltd, NSW Australia) to the nearest 0.5 cm and according to best anthropometic practice [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="22141" xml_f="22143" txt_i="16812" txt_f="16814">33</offsets></xref><offsets xml_i="22150" xml_f="22152" txt_i="16814" txt_f="16816">].</offsets></p><p><offsets xml_i="22159" xml_f="22245" txt_i="16817" txt_f="16903">Health related quality of life (HRQOL) will be assessed using the SF36 health survey [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="22277" xml_f="22279" txt_i="16903" txt_f="16905">34</offsets></xref><offsets xml_i="22286" xml_f="22290" txt_i="16905" txt_f="16909">], [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="22322" xml_f="22324" txt_i="16909" txt_f="16911">35</offsets></xref><offsets xml_i="22331" xml_f="22539" txt_i="16911" txt_f="17119">]. The SF36 comprises 11 items that ask for the participant's views about their health, how they feel and whether they are able to perform certain activities and has been tested for reliability and validity [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="22571" xml_f="22573" txt_i="17119" txt_f="17121">34</offsets></xref><offsets xml_i="22580" xml_f="22584" txt_i="17121" txt_f="17125">], [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="22616" xml_f="22618" txt_i="17125" txt_f="17127">35</offsets></xref><offsets xml_i="22625" xml_f="22950" txt_i="17127" txt_f="17452">]. A license has been obtained to use the SF36 for data collection from 300 patients on three occasions per participant (License number F1-052203-13860). SF36 scores will be coded, summed and transformed onto a scale from 0 (worst possible health) to 100 (best possible health) using the method described in the user manual [</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="22982" xml_f="22984" txt_i="17452" txt_f="17454">36</offsets></xref><offsets xml_i="22991" xml_f="22993" txt_i="17454" txt_f="17456">].</offsets></p><p><offsets xml_i="23000" xml_f="23116" txt_i="17457" txt_f="17573">Relative cardiac risk will be calculated using the LIPID score which was developed for use in secondary prevention [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="23148" xml_f="23150" txt_i="17573" txt_f="17575">37</offsets></xref><offsets xml_i="23157" xml_f="23475" txt_i="17575" txt_f="17893">]. An individual's risk score calculation involves aggregating risk point estimates corresponding to the patient's risk factor profile. Aggregate scores provide an indication of the level of risk for a future ACS. The scores are divided as low risk (≤ 4), medium risk (5–6), high risk (7–9) and very high risk (≥ 10) [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="23507" xml_f="23509" txt_i="17893" txt_f="17895">37</offsets></xref><offsets xml_i="23516" xml_f="23741" txt_i="17895" txt_f="18117">]. Further, each participants number of modifiable risk factors will be calculated using the cut points; TC &gt; 4.0 mmol/L, SBP ≥ 140 mmHg, current smoking, physical inactivity using the categorical IPAQ score, BMI ≥ 30 kg/m</offsets><sup><offsets xml_i="23746" xml_f="23747" txt_i="18117" txt_f="18118">2</offsets></sup><offsets xml_i="23753" xml_f="23806" txt_i="18118" txt_f="18171">, known diabetes and a CDS score ≥ 90 for depression.</offsets></p><p><offsets xml_i="23813" xml_f="24349" txt_i="18172" txt_f="18708">Each participant's knowledge of their own cardiovascular risk factors will also be assessed at baseline, three and 12 months. Participants will be asked if they can state any of their own modifiable risk factors for heart disease and the number stated will be compared to the each individual's actual number of modifiable risk factors. Participants will then be asked if they are able to state the Australian recommended targets for total cholesterol, BP, physical activity and whether or not smoking is recommended for people with CHD.</offsets></p></sec><sec><title><offsets xml_i="24371" xml_f="24380" txt_i="18710" txt_f="18719">Procedure</offsets></title><sec><title><offsets xml_i="24400" xml_f="24423" txt_i="18720" txt_f="18743">Conventional care group</offsets></title><p><offsets xml_i="24434" xml_f="25125" txt_i="18744" txt_f="19435">Participants randomly allocated to the conventional care group will continue to manage their heart health as directed by their primary care doctor or by their own cognisance. This group will not receive any additional intervention as a result of participation in the study. However, they will be contacted by telephone 2–3 weeks after baseline assessment to confirm their three month assessment appointment. In addition, each participant's general practitioner (GP) and cardiologist will be mailed a courtesy letter following baseline assessment and a risk factor summary with recommendations for discussion regarding long-term risk factor management following the final 12 month assessment.</offsets></p></sec><sec><title><offsets xml_i="25147" xml_f="25160" txt_i="19437" txt_f="19450">Modular group</offsets></title><p><offsets xml_i="25171" xml_f="25796" txt_i="19451" txt_f="20076">Participants randomly allocated to the modular group will manage their heart health by participation in modular guided self-choice management of heart disease. That is, participants will participate in risk factor modules of their choice, with the exception of the mandatory blood cholesterol module, strive to achieve mutually-agreed goals and make choices about risk factor reduction interventions based on their own circumstances. Following baseline assessment, the consultation will be extended by approximately 30 minutes for selection of modules, goal setting and shared decision making about risk factor interventions.</offsets></p><p><offsets xml_i="25803" xml_f="26269" txt_i="20077" txt_f="20543">The risk factor modules consist of cholesterol-lowering, BP management, smoking cessation and physical activity. All participants will participate in the cholesterol-lowering module and where applicable, participants can also choose up to two other modules depending on their individual risk factor assessment and personal preference. Therefore, all participants will participate in a minimum of one risk factor module and a maximum of three modules at any one time.</offsets></p><p><offsets xml_i="26276" xml_f="27238" txt_i="20544" txt_f="21506">The mandatory cholesterol-lowering module involves pharmacological intervention in consultation with the primary care doctor as well as education and empowerment through information and support about individual and nationally recommended cholesterol levels. The three optional modules involve choice of intervention including; following medical advice; participating in a structured program (individual or group); participating in a home program; or self-help. All risk factor modules will be resourced and delivered separately among the primary care doctor, the local area health service, the local community and the participant. Participants in the modular group will receive a resource package including appropriate information leaflets which contain guidelines and information about the module and contact information for community heart health programs. The leaflets have been developed and pilot tested, for validity, by health professionals and consumers.</offsets></p><p><offsets xml_i="27245" xml_f="27737" txt_i="21507" txt_f="21999">For each risk factor module, a three month objective goal will be set based on shared decision-making. The mutually-agreed goal will be based on the each participant's risk factor profile, social factors, commitments and personal preference. Participants will also asked to rate their confidence in achieving the set goal on a visual analogue scale from 1–10. Each risk factor baseline level, mutually agreed goal, time frame and confidence rating will be recorded on the information leaflet.</offsets></p><p><offsets xml_i="27744" xml_f="27841" txt_i="22000" txt_f="22097">All participants in the modular group will also be "coached" using a previously published model [</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="27873" xml_f="27875" txt_i="22097" txt_f="22099">38</offsets></xref><offsets xml_i="27882" xml_f="28702" txt_i="22099" txt_f="22919">]. The coaching model is a five stage cyclic process and involves assessing understanding, providing education, assertiveness training and reassessment. In this study, the first coaching session will be conducted during the initial face-to-face shared decision making, goal setting session. Participants will then be coached over the telephone on up to four further occasions, depending on goal achievement, during the following three months depending on need. Once each risk factor goal is achieved, no further coaching is required. All coaching will be conducted by a researcher who has been trained by the original coach study coordinator. During each coaching session individual's knowledge of their risk factors and personal goals will be identified and participation in the module will be established and recorded.</offsets></p><p><offsets xml_i="28709" xml_f="29742" txt_i="22920" txt_f="23953">Communication between the study coordinator, the participant and health professionals involved and community services will be facilitated where possible. Each participant will also be encouraged to communicate openly about their goals and modules with their local doctor and cardiologist. During the course of the study, participants identified as being clinically depressed, according to their CDS, are to be offered an appointment with a clinical psychologist specialising in heart disease. For each participant, their GP and cardiologist will be sent a comprehensive letter outlining the participant's risk factors, goals and chosen modules. Following the final 12 month assessment, all participants and their doctors will also receive a cardiac risk factor summary and recommendations for discussion regarding long term risk factor management. By facilitating communication, it is anticipated that each participant receives a coordinated multidisciplinary approach to their own risk factor management based on need and situation.</offsets></p></sec><sec><title><offsets xml_i="29764" xml_f="29793" txt_i="23955" txt_f="23984">Standard rehabilitation group</offsets></title><p><offsets xml_i="29804" xml_f="30752" txt_i="23985" txt_f="24933">Participants who volunteer for the standard rehabilitation group will attend the hospital-based outpatient cardiac rehabilitation program. This rehabilitation program includes twice weekly group hospital-based exercise classes for six weeks and weekly education sessions. The exercise program is supervised by a clinical nurse specialist and a physiotherapist. The exercise sessions are generally of 45 minutes duration and include a 10 minute warm up and cool down and approximately 30 minutes of cardiovascular and resistance exercise stations. These stations include leg press, treadmill walking, stair climbing, knee extension weights, stationary cycling and gentle upper limb weights. Each station is conducted for 3 minutes and patients rotate around the room from station to station with a 2 minute rest between stations. Exercise intensity is based on rating of perceived exertion (RPE) at a moderate level (3–4) on the modified RPE scale [</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="30784" xml_f="30786" txt_i="24933" txt_f="24935">39</offsets></xref><offsets xml_i="30793" xml_f="30795" txt_i="24935" txt_f="24937">].</offsets></p><p></p></sec></sec><sec><title><offsets xml_i="30830" xml_f="30841" txt_i="24941" txt_f="24952">Sample size</offsets></title><p><offsets xml_i="30852" xml_f="31056" txt_i="24953" txt_f="25157">Participant numbers required for each group have been calculated to detect a 0.5 mmol/L reduction in TC with 80% power. The LIPID study of 9014 subjects with CHD reported a mean TC of 5.6 (± 0.7) mmol/L [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="31088" xml_f="31090" txt_i="25157" txt_f="25159">40</offsets></xref><offsets xml_i="31097" xml_f="31418" txt_i="25159" txt_f="25480">] and it has been assumed that a clinically significant change in TC would be 0.5 mmol/L. Therefore, to achieve power of 80% to detect a change of 0.5 of a SD unit, using a two-tailed test with an alpha level of 0.05 and allow for 10% loss to follow-up, it was calculated that 72 participants per group will be recruited.</offsets></p></sec><sec><title><offsets xml_i="31440" xml_f="31453" txt_i="25482" txt_f="25495">Data analysis</offsets></title><p><offsets xml_i="31464" xml_f="31769" txt_i="25496" txt_f="25801">Data will be analysed by intention-to-treat using SPSS for Windows (Version 12.01) and will be presented as mean and standard error of the mean or proportions. Differences in outcome measures, between and within groups, will be compared using repeated measures ANOVAs for continuous variables and either χ</offsets><sup><offsets xml_i="31774" xml_f="31776" txt_i="25801" txt_f="25803">2 </offsets></sup><offsets xml_i="31782" xml_f="31934" txt_i="25803" txt_f="25952">tests or Fishers exact tests, as appropriate, for proportions of categorical variables. Two tailed p values of &lt; 0.05 will be considered significant.</offsets></p></sec></sec><sec><title><offsets xml_i="31962" xml_f="31972" txt_i="25955" txt_f="25965">Discussion</offsets></title><p><offsets xml_i="31983" xml_f="32214" txt_i="25966" txt_f="26197">The majority of patients with CHD do not access existing cardiac rehabilitation programs. Testing of alternative models of secondary prevention will potentially provide beneficial programs for more high risk patients following ACS.</offsets></p><p><offsets xml_i="32221" xml_f="32642" txt_i="26198" txt_f="26619">We have presented the rationale and design for a randomised controlled trial testing a modular approach to the secondary prevention of CHD. The study is also designed to compare outcomes to benchmarks set by patients participating in standard cardiac rehabilitation. The primary outcomes will be the magnitude of CHD modifiable risk factors and secondary outcomes will be relative CHD risk and knowledge of these factors.</offsets></p></sec><sec><title><offsets xml_i="32664" xml_f="32683" txt_i="26621" txt_f="26640">Competing interests</offsets></title><p><offsets xml_i="32694" xml_f="32754" txt_i="26641" txt_f="26701">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="32776" xml_f="32798" txt_i="26703" txt_f="26725">Authors' contributions</offsets></title><p><offsets xml_i="32809" xml_f="32924" txt_i="26726" txt_f="26841">JR, EE, TB and BF were responsible for the design of the study. All authors read and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="32946" xml_f="32969" txt_i="26843" txt_f="26866">Pre-publication history</offsets></title><p><offsets xml_i="32980" xml_f="33044" txt_i="26867" txt_f="26931">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2261/6/26/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors wish to thank the National Heart Foundation of Australia for their financial support in the form of a Grant-in-Aid and a Postgraduate scholarship for Julie Redfern. We also thank the participating patients and staff at Concord Hospital in the Cardiology Department for their contribution to this research.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="book"><person-group person-group-type="author"><collab>Australian Institute of Health and Welfare (AIHW)</collab></person-group><article-title>Heart, stroke and vascular diseases – Australian facts 2004</article-title><source>AIHW Cat No CVD 27</source><year>2004</year><publisher-name>Canberra: AIHW</publisher-name></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aroney</surname><given-names>C</given-names></name><name><surname>Boyden</surname><given-names>A</given-names></name><name><surname>Jelinek</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name><name><surname>Tonkin</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>H</given-names></name></person-group><article-title>Management of unstable angina, Guidelines – 2000</article-title><source>Med J Aust</source><year>2000</year><volume>173</volume><fpage>S65</fpage><lpage>S88</lpage><pub-id pub-id-type="pmid">11109929</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McAlister</surname><given-names>FA</given-names></name><name><surname>Lawson</surname><given-names>FME</given-names></name><name><surname>Teo</surname><given-names>KK</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name></person-group><article-title>Randomised trials of secondary prevention programs in coronary heart disease: systematic review</article-title><source>Br Med J</source><year>2001</year><volume>323</volume><fpage>957</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">11679383</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>WH</given-names></name><name><surname>Lay</surname><given-names>CP</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name></person-group><article-title>Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients</article-title><source>Lancet</source><year>1993</year><volume>341</volume><fpage>1496</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">8099379</pub-id><pub-id pub-id-type="doi">10.1016/0140-6736(93)90634-S</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panza</surname><given-names>JA</given-names></name><name><surname>Quyyumi</surname><given-names>AA</given-names></name><name><surname>Callahan</surname><given-names>TS</given-names></name><name><surname>Epstein</surname><given-names>SE</given-names></name></person-group><article-title>Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension</article-title><source>J Am Coll Cardiol</source><year>1993</year><volume>21</volume><fpage>1145</fpage><lpage>1151</lpage><pub-id pub-id-type="pmid">8459069</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>RS</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Ebrahim</surname><given-names>S</given-names></name><name><surname>Jolliffe</surname><given-names>J</given-names></name><name><surname>Noorani</surname><given-names>H</given-names></name><name><surname>Rees</surname><given-names>K</given-names></name><name><surname>Skidmore</surname><given-names>B</given-names></name><name><surname>Stone</surname><given-names>JA</given-names></name><name><surname>Thompson</surname><given-names>DR</given-names></name><name><surname>Oldridge</surname><given-names>N</given-names></name></person-group><article-title>Exercise-based rehabilitation for patients with coronary heart disease: a systematic review and meta-analysis of randomized trials</article-title><source>Am J Med</source><year>2004</year><volume>116</volume><fpage>682</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">15121495</pub-id><pub-id pub-id-type="doi">10.1016/j.amjmed.2004.01.009</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bunker</surname><given-names>S</given-names></name><name><surname>McBurney</surname><given-names>H</given-names></name><name><surname>Cox</surname><given-names>H</given-names></name><name><surname>Jelinek</surname><given-names>M</given-names></name></person-group><article-title>Identifying participation rates at outpatient cardiac rehabilitation programs in Victoria, Australia</article-title><source>Journal of Cardiopulmonary Rehabilitation</source><year>1999</year><volume>19</volume><fpage>334</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">10609180</pub-id><pub-id pub-id-type="doi">10.1097/00008483-199911000-00001</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>IA</given-names></name><name><surname>Lindsay</surname><given-names>KA</given-names></name><name><surname>Harden</surname><given-names>HE</given-names></name></person-group><article-title>Utilisation of outpatient cardiac rehabilitation in Queensland</article-title><source>Med J Aust</source><year>2003</year><volume>179</volume><fpage>341</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">14503895</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evenson</surname><given-names>KR</given-names></name><name><surname>Fleury</surname><given-names>J</given-names></name></person-group><article-title>Barriers to outpatient cardiac rehabilitation participation and adherence</article-title><source>J Cardiopul Rehab</source><year>2000</year><volume>20</volume><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1097/00008483-200007000-00005</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harlan</surname><given-names>WR</given-names></name><name><surname>Sandler</surname><given-names>SA</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Lam</surname><given-names>LC</given-names></name><name><surname>Mark</surname><given-names>DB</given-names></name></person-group><article-title>Importance of baseline functional and socioeconomic factors for participation in cardiac rehabilitation</article-title><source>Am J Cardiol</source><year>1995</year><volume>76</volume><fpage>36</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">7793400</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(99)80797-8</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sundarajan</surname><given-names>V</given-names></name><name><surname>Bunker</surname><given-names>SJ</given-names></name><name><surname>Begg</surname><given-names>S</given-names></name><name><surname>Marshall</surname><given-names>R</given-names></name><name><surname>McBurney</surname><given-names>H</given-names></name></person-group><article-title>Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998</article-title><source>Med J Aust</source><year>2004</year><volume>180</volume><fpage>268</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">15012563</pub-id></citation></ref><ref id="B12"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Briffa</surname><given-names>T</given-names></name></person-group><article-title>Costs and benfits of existing and new cardiac rehabilitation strategies</article-title><source>Unpublished PhD Thesis, Faculty of Medicine, University of Sydney</source><year>2000</year></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merz</surname><given-names>CNB</given-names></name><name><surname>Rozanski</surname><given-names>A</given-names></name></person-group><article-title>Remodeling cardiac rehabilitation into secondary prevention programs</article-title><source>Am Heart J</source><year>1995</year><volume>132</volume><fpage>418</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">8701906</pub-id></citation></ref><ref id="B14"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WR</given-names></name><name><surname>Rollnick</surname><given-names>S</given-names></name></person-group><source>Motivational Interviewing: Preparing people for change</source><year>2002</year><edition>2</edition><publisher-name>The Guilford Press: New York</publisher-name></citation></ref><ref id="B15"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Coulter</surname><given-names>A</given-names></name><name><surname>Entwistle</surname><given-names>V</given-names></name><name><surname>Gilbert</surname><given-names>D</given-names></name></person-group><source>Informing patients: An Assessment of the Quality of Patient Information Material</source><year>1998</year><publisher-name>London: King's Fund</publisher-name></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulman</surname><given-names>BA</given-names></name></person-group><article-title>Active patient orientation and outcomes in hypertensive treatment</article-title><source>Med Care</source><year>1979</year><volume>17</volume><fpage>267</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">763004</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>M</given-names></name><name><surname>Buckman</surname><given-names>R</given-names></name><name><surname>Stewart</surname><given-names>M</given-names></name><name><surname>Maguire</surname><given-names>P</given-names></name><name><surname>Lipkin</surname><given-names>M</given-names></name><name><surname>Novack</surname><given-names>D</given-names></name><name><surname>Till</surname><given-names>J</given-names></name></person-group><article-title>Doctor-patient communication: the Toronto consensus statement 1991</article-title><source>BMJ</source><year>1991</year><volume>303</volume><fpage>1385</fpage><lpage>1387</lpage><pub-id pub-id-type="pmid">1760608</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brody</surname><given-names>DS</given-names></name><name><surname>Miller</surname><given-names>SM</given-names></name><name><surname>Lerman</surname><given-names>CE</given-names></name><name><surname>Smith</surname><given-names>DG</given-names></name><name><surname>Caputo</surname><given-names>GC</given-names></name></person-group><article-title>Patient perception of involvement in medical care: relationship to illness attitudes and outcomes</article-title><source>J Gen Intern Med</source><year>1989</year><volume>4</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">2585158</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>MA</given-names></name></person-group><article-title>Effective physician-patient communication and health outcomes: A review</article-title><source>CMAJ</source><year>1995</year><volume>152</volume><fpage>1423</fpage><lpage>1433</lpage><pub-id pub-id-type="pmid">7728691</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roter</surname><given-names>DL</given-names></name></person-group><article-title>Patient participation in patient provider interaction: the effects of patient question-asking on the quality of interaction, satisfaction and compliance</article-title><source>Health Educ Monogr</source><year>1997</year><volume>5</volume><fpage>281</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">346537</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>SH</given-names></name><name><surname>Greenfield</surname><given-names>S</given-names></name><name><surname>Ware</surname><given-names>JE</given-names></name></person-group><article-title>Assessing the effects of physician-patient interactions on the outcomes of chronic disease</article-title><source>Med Care</source><year>1989</year><volume>27</volume><fpage>S110</fpage><lpage>S127</lpage><pub-id pub-id-type="pmid">2646486</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coulter</surname><given-names>A</given-names></name></person-group><article-title>Partnerships with patients: the pros and cons of shared clinical decision-making</article-title><source>J Health Serv Res Policy</source><year>1997</year><volume>2</volume><fpage>112</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">10180362</pub-id></citation></ref><ref id="B23"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Rollnick</surname><given-names>S</given-names></name><name><surname>Allison</surname><given-names>J</given-names></name><name><surname>Ballasiotes</surname><given-names></given-names></name><name><surname>Barth</surname><given-names>T</given-names></name><name><surname>Butler</surname><given-names>CC</given-names></name><name><surname>Rose</surname><given-names>GS</given-names></name><name><surname>Rosengren</surname><given-names>DB</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Miller WR, Rollnick S</surname></name></person-group><article-title>Variations on a theme: motivational interviewing and its adaptations (Chap 18)</article-title><source>Motivational Interviewing: Preparing people for change</source><year>2002</year><edition>2</edition><publisher-name>The Guilford Press: New York</publisher-name></citation></ref><ref id="B24"><citation citation-type="book"><person-group person-group-type="author"><collab>Commonwealth Department of Health and Aging</collab></person-group><article-title>Australian Refined Diagnosis Related Groups</article-title><source>Version 41</source><year>1998</year><volume>1</volume><publisher-name>Commonwealth of Australia: Canberra</publisher-name></citation></ref><ref id="B25"><citation citation-type="other"><article-title>Randomization.com [Homepage on the Internet]: Dallal GE [updated 2003 May 28]</article-title><ext-link ext-link-type="uri" xlink:href="http://www.randomization.com"></ext-link><comment>[Accessed: June 1 2003]</comment></citation></ref><ref id="B26"><citation citation-type="other"><person-group person-group-type="author"><collab>Instruction Manual</collab></person-group><article-title>Digital Automatic Blood Pressure Monitor Model M6 [manual on the internet] [Updated: 2004 July 14]</article-title><ext-link ext-link-type="uri" xlink:href="http://www.omron-healthcare.com/site/index.cfm?BID=3&amp;SID=1&amp;TID=1&amp;MID=1&amp;ART=324&amp;LG=2&amp;back=1"></ext-link><comment>[Accessed: January 2 2006]</comment></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El Assaad</surname><given-names>MA</given-names></name><name><surname>Topouchian</surname><given-names>J</given-names></name><name><surname>Asmar</surname><given-names>RG</given-names></name></person-group><article-title>Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron MS-I and the Omron 705IT</article-title><source>Blood Press Monit</source><year>2003</year><volume>8</volume><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">12900590</pub-id></citation></ref><ref id="B28"><citation citation-type="other"><person-group person-group-type="author"><collab>National Blood Pressure Advisory Committee</collab></person-group><article-title>Hypertension Management Guide for Doctors [monograph on the internet]</article-title><ext-link ext-link-type="uri" xlink:href="http://www.heartfoundation.com.au/index.cfm?page=36"></ext-link><comment>[Accessed 2005 March 25)</comment></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>N</given-names></name><name><surname>Idle</surname><given-names>M</given-names></name><name><surname>Boreham</surname><given-names>J</given-names></name><name><surname>Bailoey</surname><given-names>A</given-names></name></person-group><article-title>Carbon monoxide in breath in relation to smoking and carboxyhaemoglobin levels</article-title><source>Thorax</source><year>1981</year><volume>36</volume><fpage>366</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">7314006</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>M</given-names></name></person-group><article-title>Assessment of physical activity: an international perspective</article-title><source>Res Q Exerc Sport</source><year>2000</year><volume>71</volume><fpage>S114</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">10925833</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>CL</given-names></name><name><surname>Marshall</surname><given-names>AL</given-names></name><name><surname>Sjostrom</surname><given-names>M</given-names></name><name><surname>Bauman</surname><given-names>AE</given-names></name><name><surname>Booth</surname><given-names>ML</given-names></name><name><surname>Ainsworth</surname><given-names>BE</given-names></name><name><surname>Pratt</surname><given-names>M</given-names></name><name><surname>Ekelund</surname><given-names>U</given-names></name><name><surname>Yngve</surname><given-names>A</given-names></name><name><surname>Sallis</surname><given-names>JF</given-names></name><name><surname>Oja</surname><given-names>P</given-names></name></person-group><article-title>International physical activity questionnaire: 12-country reliability and validity</article-title><source>Med Sci Sports Exerc</source><year>2003</year><volume>35</volume><fpage>1381</fpage><lpage>1395</lpage><pub-id pub-id-type="pmid">12900694</pub-id><pub-id pub-id-type="doi">10.1249/01.MSS.0000078924.61453.FB</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>DL</given-names></name><name><surname>Davis</surname><given-names>CR</given-names></name></person-group><article-title>Cardiac depression scale: Validation of a new depression scale for cardiac patients</article-title><source>J Psychosom Res</source><year>1996</year><volume>40</volume><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">8736418</pub-id><pub-id pub-id-type="doi">10.1016/0022-3999(95)00612-5</pub-id></citation></ref><ref id="B33"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Norton</surname><given-names>K</given-names></name><name><surname>Olds</surname><given-names>T</given-names></name><collab>Eds</collab></person-group><source>Anthropometrica: a textbook of body measurement for sports and health courses</source><year>1996</year><publisher-name>Sydney Australia, UNSW Press</publisher-name></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Sherbourne</surname><given-names>CD</given-names></name></person-group><article-title>The MOS 36-item short-form health survey (SF36) I Conceptual framework and item selection</article-title><source>Med Care</source><year>1992</year><volume>30</volume><fpage>473</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">1593914</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Gandek</surname><given-names>BG</given-names></name><name><surname>Aaronson</surname><given-names>N</given-names></name><name><surname>Alonso</surname><given-names>J</given-names></name><name><surname>Apolone</surname><given-names>G</given-names></name><name><surname>Bech</surname><given-names>P</given-names></name><name><surname>Brazier</surname><given-names>J</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Kaasa</surname><given-names>S</given-names></name><name><surname>Leplège</surname><given-names>A</given-names></name><name><surname>Prieto</surname><given-names>L</given-names></name><name><surname>Sullivan</surname><given-names>M</given-names></name></person-group><article-title>The Factor Structure of the SF-36<sup>® </sup>Health Survey in 10 Countries: Results from the International Quality of Life Assessment (IQOLA) Project</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><fpage>1159</fpage><lpage>1165</lpage><pub-id pub-id-type="pmid">9817133</pub-id><pub-id pub-id-type="doi">10.1016/S0895-4356(98)00107-3</pub-id></citation></ref><ref id="B36"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Snow</surname><given-names>KK</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Gandek</surname><given-names>B</given-names></name></person-group><source>SF-36<sup>® </sup>Health Survey Manual and Interpretation Guide 1993</source><year>1993</year><publisher-name>Boston, MA: New England Medical Center, The Health Institute</publisher-name></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marschner</surname><given-names>IC</given-names></name><name><surname>Colquhoun</surname><given-names>D</given-names></name><name><surname>Simes</surname><given-names>RJ</given-names></name><name><surname>Glasziou</surname><given-names>P</given-names></name><name><surname>Harris</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>BB</given-names></name><name><surname>Friedlander</surname><given-names>D</given-names></name><name><surname>White</surname><given-names>H</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name><name><surname>Tonkin</surname><given-names>A</given-names></name></person-group><article-title>Long-term risk stratification for survivors of acute coronary syndromes</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>38</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">11451296</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(01)01360-2</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vale</surname><given-names>M</given-names></name><name><surname>Jelinek</surname><given-names>M</given-names></name><name><surname>Best</surname><given-names>JD</given-names></name><name><surname>Santamaria</surname><given-names>JD</given-names></name></person-group><article-title>Coaching patients with coronary heart disease to achieve the target cholesterol: A method to bridge the gap between evidence-based medicine and the "real world" – randomized controlled trial</article-title><source>J Clin Epidemiol</source><year>2002</year><volume>55</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">11864795</pub-id><pub-id pub-id-type="doi">10.1016/S0895-4356(01)00460-7</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>GV</given-names></name></person-group><article-title>Psychophysical bases of perceived exertion</article-title><source>Med Sci Sports Exerc</source><year>1982</year><volume>14</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">7154893</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simes</surname><given-names>JR</given-names></name><name><surname>Marschener</surname><given-names>IC</given-names></name><name><surname>Hunt</surname><given-names>D</given-names></name><name><surname>Colquhoun</surname><given-names>D</given-names></name><name><surname>Sullivan</surname><given-names>D</given-names></name><name><surname>Stewart</surname><given-names>RA</given-names></name><name><surname>Hague</surname><given-names>W</given-names></name><name><surname>Keech</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name><name><surname>White</surname><given-names>H</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><name><surname>Tonkin</surname><given-names>A</given-names></name></person-group><article-title>Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischaemic disease (LIPID) trial: To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?</article-title><source>Circulation</source><year>2002</year><volume>105</volume><fpage>1162</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">11889008</pub-id><pub-id pub-id-type="doi">10.1161/hc1002.105136</pub-id></citation></ref></ref-list></back></article>